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I. Executive Summary 
 
Glioblastoma multiforme is a high-grade malignant glioma, caused by rapidly 
proliferating, metastasizing astrocytes in the brain
[2,3,4,5]
. This glioma has an average survival 
time of 12 months post-diagnosis and results in approximately 13,000 deaths annually
[6,7]
. The 
primary treatment protocol for this glioma involves delivering carmustine (BCNU) drug using 
the commercially available Gliadel
®
 wafer following surgical tumor resection and radiation 
treatment
[2]
.  Drug penetration using the wafer, however, only extends to a maximum distance of 
1.00 cm away from the resected tumor. Ideally, to prevent the recurrence of malignant gliomas, 
threshold levels of BCNU (0.0252 mol/m
3
) should be present up to 2.50 cm from the outer 
boundary of the remaining tumor margin
[8]
.  The purpose of our study is to model a new drug 
delivery method for treatment of glioblastoma multiforme (GBM).  
Our new approach is to incorporate BCNU into nanoparticles and then uniformly 
distribute these BCNU-loaded nanoparticles into a scaffold made of the same material used for 
Gliadel
®
 wafers.  Hence we examined the release of BCNU from polylactic acid (PLA) 
nanoparticles originally contained in a pCPP:SA scaffold (1,3-bis(p-carboxyphenoxy)propane 
(CPP) and sebacic acid (SA) in a 20 to 80 molar ratio) similar to the wafer material of Gliadel
®
.  
Further diffusion of the drug into the tumor and normal brain tissue regions is expected because 
the BCNU is protected from enzymatic degradation while within the nanoparticles. 
In COMSOL, the scaffold, tumor tissue, and healthy brain tissue were modeled as a 
compound hemispherical region in a 2D, axisymmetric geometry with two transient diffusion 
species.  The 1 mm thick scaffold contained uniformly distributed nanoparticles that were 
released by diffusion through the scaffold.  BCNU was released from the nanoparticles over time 
before diffusing further on its own.  A BCNU release profile obtained from the specific 
nanoparticle-BCNU formulation by Yan et al
[9]
. was used to make a BCNU generation term as a 
function of nanoparticle concentration and time.  A 36 hour delay was also included in the flux 
function to represent an outer shell around the nanoparticle that would prevent BCNU release 
until 36 hours after implantation. 
 After running the COMSOL simulation for ten days, the results for the encapsulated 
BCNU nanoparticle model indicate that the furthest distance at which a therapeutically effective 
concentration of BCNU is present is 2.967 cm from the center of the resected tumor, which is 
0.467 cm from the edge of the resected tumor. The results for the non-encapsulated BCNU show 
the effective distance is 3.227 cm from the center of the resected tumor, which is 0.727 cm from 
the edge of the resected tumor. As such, the scaffold/nano-particle drug delivery approach 
appears to be significantly less effective in delivering threshold concentration levels of BCNU to 
further distances from the resection site in comparison to the wafer method. While our method 
does not increase the effective distance, the encapsulation protects the drug from degradation 
thereby significantly increasing its post-implantation half-life. 
Increasing the distance of therapeutic BCNU delivery to the target regions would 
significantly improve the number of glioma cells eradicated by the treatment and prolong the life 
of those who are diagnosed with glioblastoma multiforme.  However, our results indicate that 
nanoparticles, at least in our formulation, were not useful to such ends.  Further study is required 
in order to confirm such findings for other nanoparticle formulations. 
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II. Introduction 
 
Glioblastoma multiforme is a high-grade malignant glioma, caused by rapidly 
proliferating, metastasizing astrocytes in the brain
[2,3,4,5]
. Almost 52% of all brain tumor cases are 
glioblastoma multiforme
[4]
. This glioma has an average survival time of 12 months post-
diagnosis and results in approximately 13,000 deaths annually
[6,7]
. Glioblastoma multiforme is 
extremely difficult to treat because the tumors are heterogeneous and the tumor cells penetrate 
the adjacent regions of the brain and therefore cannot be entirely removed during surgical 
removal. Current treatment approaches include: radiation therapy, chemotherapy, gene therapy, 
surgery or a combination of two or more
[10]
.  The treatment chosen is highly predicated on the 
characteristics of the tumor, how quickly it proliferates, the symptoms it induces, and its location 
in the brain
[10]
. Furthermore, most glioma cells are partly resistant to radiation and 
chemotherapy
[4,11]
. A significant hindrance to the delivery of chemotherapeutic agents to areas in 
the central nervous system is the existence of the blood brain barrier, new methods of intracranial 
drug delivery are being investigated to release potent concentrations of drug to tumor cells, while 
evading the undesirable systemic effects
[11]
. There is a pressing need to develop more effective 
methods to improve treatment approaches and to produce higher life expectancies.  
All treatment modes intend to initially maximize the number of tumor cells eradicated.  
Generally surgery is first done to remove the bulk of the initial tumor cells.  The remaining 
carcinogenic cells are then removed using radiation and chemotherapy
[4,11]
. Unfortunately, high-
grade gliomas like glioblastoma multiforme have a high propensity for re-growth, and available 
treatments can only attempt to delay their recurrence as long as possible
[11]
. In one 
chemotherapeutic approach to treat recurrent gliomas, surgeons perform a craniotomy to 
surgically resect most of the tumor leaving a 2.00 mm margin of cancerous tissue.  Up to eight 
Gliadel
®
 wafers are then placed in the resection cavity for the directed and controlled release of 
BCNU, a drug used to kill the remaining glioma cells
[2,12]
. Each Gliadel
®
 wafer (diameter: 14.5 
mm, thickness: 1.00 mm) is composed of a 20:80 molar ratio poly[bis(p-carboxyphenoxy) 
propane: sebacic acid] (p(CPP:SA, 20:80)) and contains 7.7 mg of homogenously distributed 
BCNU.  BCNU is a chemotherapeutic drug that has proved effecting in killing glioma cells.  The 
wafers degrade over two to three weeks, allowing the drug to diffuse into the proximate 
tissue
[2,12]
. 
The goal of all treatments for glioblastoma multiforme is to eradicate all glioma cells up 
to 2.5 cm from the outer tumor boundary.  Gliadel
®
 wafer treatment has been found to extend 
only 1.00 cm from the outer tumor boundary.  Thus, we chose to study the efficiency of a new 
treatment approach in which BCNU is encapsulated in nanoparticles to extend the drug’s half-
life post-implantation and allow functional BCNU to reach further into the target region.  The 
scaffold/nano-particle method presented examines the release of BCNU drug from polylactic 
acid (PLA) nanoparticles contained in a pCPP:SA scaffold using a 2D axisymmetric, transient 
diffusion COMSOL model.  We expect this model will ensure further diffusion of the BCNU 
into the tumor and normal brain tissue regions by postponing degradation of the drug. 
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II.A Design Objectives 
 
Using COMSOL, we will model the concentration profile of PLA nanoparticles diffusing out 
of a pCPP:SA scaffold and of BCNU released from these nanoparticles in order to:   
I. Determine how the concentration of the carmustine (BCNU) in the tumor region changes 
over time (concentration profile) 
II. Determine the difference in the effective radius of the BCNU in the brain by comparing 
nano-particle encapsulated BCNU release from scaffold to free BCNU release from 
scaffold (like Gliadel
®
).  
 
II.B Problem Schematic 
 
A 2D axisymmetric, transient diffusion COMSOL model will be used, in which we 
expected further diffusion of the drug into the tumor and normal brain tissue regions due to 
protection of BCNU from degradation while contained in the nanoparticles.  The scaffold, tumor 
tissue, and healthy brain tissue were modeled as a compound hemispherical region with a 1 mm 
thick scaffold composed of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 
20 to 80 molar ratio (p(CPP:SA, 20:80)), a 2mm thick tumor region, and semi-infinitely thick 
(2.5cm) healthy tissue region. Initially, the pCPP:SA scaffold contains uniformly distributed 
nano-particles to be released by diffusion. The PLA nanoparticles contain BCNU, which is 
released via surface erosion over time by a function extrapolated from release profile data 
obtained by Yan et al (see Appendix A).  A 36 hour delay was also included in flux function to 
represent an outer layer around the nanoparticle that would prevent BCNU release until 36 hours 
post-implantation. 
 
We present our treatment as an analysis of 2-species: 
I. Nanoparticle concentration 
II. BCNU concentration 
 
 
Figure 1. Schematics. A) Gliadel
®
 Implantation. After surgical tumor resection, up to 8 Gliadel
®
 wafers are 
added to release BCNU into the surrounding tissue. B) pCPP:SA Scaffold Schematic. The tumor to be resected is 
50.0 mm in diameter and the margins after surgery are 2.0 mm. The required scaffold is 1mm thick with an outer 
diameter of 46.0 mm. C) Simplified Schematic. PLA Nanoparticles (54nm diameter) impregnated with BCNU 
diffusing through the pCPP:SA scaffold and tumor tissue.   
A) B) C) 
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III. Results and Discussion 
III.A Concentration Profiles 
 
To determine the effective release of drug into the tumor region, simulations of PLA 
nanoparticles and BCNU diffusion (Figures 6 and 7) were run for 10 days.  To uncover how the 
drug and nanoparticles have moved through the target regions by the end of the simulation, 
surface concentration plots were generated in COMSOL and are presented below.  These plots 
show the concentration profiles of the species at the final time of 10 days.  
 
 
Figure 6. Surface Plot of PLA nanoparticle concentration at 10 days (mol/m
3
).  The diffusion of PLA 
nanoparticles (54nm) carrying BCNU drug though the scaffold, tumor region, and healthy brain tissue after 10 days. 
 
 
 
 
 
 
Figure 7. Surface Plot of BCNU Concentration at 10 days (mg/m
3
). The diffusion of BCNU drug through the 
scaffold, tumor region, and healthy brain tissue after 10 days. 
 
As can be seen in Figure 6, the nanoparticle penetrates into the healthy tissue region by 
the end with a concentration greater than 5x10
-3
mol/m
3
 about 5mm into this region (r=0.03m). 
As can be seen in Figure 7, the final BCNU concentration profile shows that drug concentration 
is approximately 4000 mg/m
3
 the within the tumor region (0.023≤ r ≤0.025 m) which is less than 
the threshold level of  5392.8 mg/m
3
.  It certainly can be seen that by the final time point of our 
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simulation, drug degradation has taken the BCNU concentration within the tissues down to 
below threshold.  However, prior to the final time, BCNU concentrations above threshold are 
obtained as can be seen below.  
 
 
 
Figure 8. BCNU Concentration Profiles with Nanoparticles at 0, 2, 4, 6, 8, and 10 days. After a 36-hour delay the 
nanoparticles will release BCNU into the scaffold, tumor region, and healthy tissue region. The drastic release profile shown at 2 
days comes from the initial bulk BCNU discharge from the nanoparticles. Shortly after two days, significantly less BCNU is 
released from the nanoparticle. 
 
After one and a half days post-implantation, the nanoparticles begin to release BCNU; 
this is visible in Figure 8 at the 2 day time point. As the nanoparticles begin to diffuse through 
the domain, we see that the reach of the BCNU appears to be dependent on the nanoparticle 
release profile (see Figure 15, Appendix A). Figure 8 also points to the conclusion that maximum 
BCNU concentrations occur around the end of the quick release period.  
 
In order to determine the maximum concentration at any distance throughout the 
simulation, plotting of the concentration gradients every hour is essential.  With the profiles from 
all times in the simulation overlaid on one plot as in Figure 9, effective distance is ascertained by 
determining where the maximum concentration corresponds to the threshold BCNU level 
required for sufficient glioma cell death. 
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Figure 9. BCNU Concentration Profiles with Nanoparticles at every hour. The concentration profiles of BCNU at every 
successive hour during the simulation over a period of 10 days had lower maximum concentrations. 
 
As evident above, the BCNU concentration profile decreases with time.  At all times, the 
slope of the concentration gradients is lowest in the tumor region. This occurs because the tumor 
region has a diffusivity that is an order of magnitude higher than that of the scaffold and healthy 
tissue regions. The tumor and healthy tissue regions also show exponential decay in BCNU 
concentration due to the degradation of drug. This decay is not as visible in the tumor region 
where high diffusivity causes a low concentration gradient. From Figure 9, we ascertain that the 
effective distance of this model is 0.00467m from the scaffold, 0.02967m from the center of the 
resected tumor. 
 
The reason for the limited reach of BCNU into the healthy region can be attributed to its 
dependence on nanoparticle diffusion.  Nanoparticle concentration profiles provide insight into 
this dependence since the nanoparticles must travel into the region before most of the BCNU can 
be released.   
 
 
Figure 10. Nanoparticle Concentration Profiles at 0, 2, 4, 6, 8, and 10 days. Gradient-dependent nanoparticle release from the 
scaffold every two days for a period of 10 days. The concentration gradient decreases as fewer nanoparticles are released from 
the scaffold over time.  
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Initially, the concentration of the nanoparticle in the scaffold/tumor boundary is at its 
highest level as indicated by the dark blue curve. The initial concentration of nanoparticles 
within the scaffold region is at its highest, around 1.7 x 10
-3
 mol/m
3
, but decreases rapidly as 
seen in the day 2 curve. After the initial implantation day, the nanoparticle concentration drops 
by about 10
-3
 mol/m
3
. As time increases, the rate of nanoparticle diffusion into the tumor region 
and healthy tissue region decreases causing a progressive decrease in concentration gradient as 
shown by the slopes of the concentration profiles.   
 
To determine how our model may compare to the commercially available Gliadel
®
, we 
developed a Gliadel-like model in which BCNU was released directly from the pCPP:SA 
scaffold without the use of nanoparticles.  Therefore, the BCNU released and the effective 
distance traveled can be obtained by comparing the BCNU concentration profiles with and 
without the use of nanoparticles. 
 
 
 
 
Figure 11. BCNU Concentration Profiles without Nanoparticles at 0, 0.5, 1, 1.5, and 2 days. The majority of the BCNU held 
within the scaffold is released and diffuses through the tumor and healthy tissues regions in less than 1 day. 
 
Unlike the release in the nanoparticle case, the non-encapsulated BCNU is able to 
traverse the domain in a much smaller time period (Figure 8).  This indicates that the 
nanoparticles are able to hold the BCNU for significantly longer periods of time as it moves 
through the tissue. The model lacking the nanoparticles allows for greater distance of BCNU 
diffusion into the healthy tissue region, with BCNU extending almost 0.005m farther than in the 
nanoparticle model.  Figure 11 shows that most of the BCNU is consumed by 2 days post-
implantation. Comparing Figure 8 and Figure 11, we see an order of magnitude difference 
between the concentration remaining at the 2 day mark for the no-nanoparticle model and at the 
10 day mark for the nanoparticle model. We can presume the more sustained presence of BCNU 
is due to the nanoparticles protecting the drug from degradation.  This drastic difference would 
not be possible without the use of nanoparticles.  
 
In the model without nanoparticles the BCNU concentration profiles (Figure 12) decrease 
with time, similarly to that in the simulation where nanoparticles were used.   
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Figure 12. BCNU Concentration Profiles without Nanoparticles at every hour. The concentration profiles of BCNU at every 
successive hour during the simulation over a period of 10 days had lower maximum concentrations. 
 
For all time points, the slope of the concentration gradients is also lowest in the tumor 
region because of the high diffusivity in this medium.  After the initial day, both the tumor and 
healthy tissue regions express a sharp exponential decay in BCNU concentration which is 
attributed to the degradation of drug.  In comparison to the steepness of the decay in the healthy 
tissue region, the slope of the concentration gradient in the tissue region is flatter because the 
high diffusivity produces a lower concentration gradient.  Using an expanded version of this plot, 
the effective distance of BCNU release without nanoparticles was determined to be 0.00727m 
from the tumor region (0.03227m from the center of the resected tumor), which is almost twice 
as far as our nanoparticle-encapsulated model.   
III.B. Mesh Convergence 
 
In order to ensure that our mesh converged and to eliminate the potential discretization 
error sometimes caused by coarse meshes, the solutions of several different meshes 3 days into 
the simulation were analyzed.  We analyzed their convergence by obtaining the average 
concentration within the tumor region and the flux at a point along the tumor-healthy tissue 
interface. Using these values, the relative percent change in the average concentration within the 
tumor region and the relative percent change flux at a point along the tumor-healthy interface 
were calculated to demonstrate mesh convergence (Figure 12).  
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Figure 12. Mesh Convergence. A) Mesh Convergence of Average BCNU Concentration in the Tumor Region with and 
without Nanoparticles.  Even at the lowest number of elements, the relative percent change in average BCNU concentration is 
less than 1% for the nanoparticle case and less than 1.5% for the no nanoparticle case. B)  Mesh Convergence of BCNU Flux at 
a Point on the Tumor-Healthy Tissue Interface. Even at the lowest number of elements, the relative percent change in BCNU 
flux is less than 1% for the nanoparticle case and less than 1.5% for the no nanoparticle case 
 
It was found that even at the lowest number of elements, the relative percent change in 
average BCNU concentration was less than 1% and 1.5% in the nanoparticle case and no 
nanoparticle case respectively while the relative percent change in flux was less than 1% and 
1.5% as well for the nanoparticle case and no nanoparticle case respectively.  As such, we could 
have chosen to use meshes of fewer than 1000 elements for both models.  However, as it did not 
take very long to solve when the number of elements was increased, we chose to err on the side 
of caution and went with the meshes shown in Figure 13. 
 
 
Figure 13. The Final Meshes. A) Final Mesh for Nanoparticle Model with 2220 elements. B) Final Mesh for No 
Nanoparticle Model with 6818 elements 
 
All meshes produced a solution with the same general shape and we found that the mesh 
converged by 198 elements for the nanoparticle model and by 1050 elements for the no 
nanoparticle model.  Therefore, a mesh of 2220 elements and 6818 elements were chosen for the 
nanoparticle model and no nanoparticle model, respectively.  
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III.C Accuracy Check 
 
An analytical solution characterizing BCNU diffusion from pCPP:SA scaffolds shows 
that the effective distance of the drug is 1.018 cm from the polymer site (Appendix C3). Past 
research conducted on BCNU diffusion from pCPP:SA scaffolds has also demonstrated that the 
effective distance of the drug is about 1 cm from the polymer site
[13]
.  However, our COMSOL 
model of this same condition gave a predicted result of .727 cm from the polymer site, as seen in 
Figure 12, which is about 30% smaller than the analytical solution and the results found in the 
literature. 
The discrepancy between our model and the analytical solution may be due to the fact 
that the latter models one-dimensional diffusion of the drug, whereas the former models two-
dimensional diffusion. The discrepancy between our model and past studies may be due to 
several additional factors. First, the penetration distance listed in the literature could have been 
defined as the distance at which no more BCNU is present, whereas we defined this distance be 
the one at which the BCNU concentration is minimally effective. This definition would make 
their penetration distance larger. Second, we assumed the degradation rate of the BCNU to be a 
first order reaction. However, if the degradation were actually a zero order reaction, the 
minimally effective BCNU concentration could be able to go further out into the brain tissue.  
The lack of agreement between the experimental and theoretical penetration distances 
raises questions about the accuracy of our model. However, because the implementations for our 
models with and without the nanoparticle are otherwise identical, we are still able to compare the 
two COMSOL models to each other.  
 
III.D Sensitivity Analysis 
 
Sensitivity of our model to various input parameters was assessed based on the result of 
parameter modification on the effective radius of BCNU outside of the tumor region.  Results, 
which are shown in Figure 14, show low sensitivity to changes in realistic diffusivity values, to 
the span of quick release of BCNU from nanoparticles, and to the delay time of release from our 
nanoparticles.  They do however show relatively high sensitivity to the rate of BCNU 
degradation and initial BCNU concentration.  
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Figure 14. Sensitivity Analysis. A) Nanoparticle Diffusivity was adjusted by orders of magnitude and the 
effective radii of the formulations were compared. B) Time of Release Delay was adjusted from 0 hours to 48 hours 
and the effective radii of the formulations were compared with the 36hour delay as the baseline. C) BCNU 
degradation rate was adjusted by various percentages and the effective radii of the formulations were compared. D) 
BCNU concentration in nanoparticles was adjusted by various percentages and the effective radii of the 
formulations were compared.  For each adjustment, there was a trial where the mass of drug administered was 
allowed to change with the initial concentration and one where the nanoparticle concentration was also adjusted in 
order to keep the total mass of drug administered the same. E) Span of Quick Release was adjusted and lengthened 
by various percentages in order to increase the percent of BCNU introduced to the nanoparticles that would come 
out during the period when the nanoparticles released 1.72% of their contents per hour. 
III.D.i Diffusivity 
 Due to the high uncertainty of our Stokes-Einstein estimated diffusivity values, 
sensitivity of the model to nanoparticle diffusivity was assessed based on magnitudinal changes 
in diffusivity values.  Results, seen in Figure 14A, show a very large increase in effective range 
when the magnitude of diffusivity was increased.  However, due to the fact that the viscosities of 
brain tissue and scaffold are more likely to be higher than that of water, it is much more likely 
A) B) 
C) D) 
E) 
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that the actual diffusivities of the nanoparticles would be lower than our inputs and not higher.  It 
should also be noted that the ~450% difference obtained and reported for the +2 magnitude value 
is likely different from the true increase of a +2 magnitude alteration on nanoparticle 
diffusivity.  In this case, our semi-infinite geometry assumption failed, as the entire region had a 
maximum BCNU concentration greater than the effective dose.  It is possible that extending the 
simulation region could both increase or decrease this value, but as stated, such a diffusivity 
would be unlikely to be realized. 
Compared to the effect of increased diffusivities, the effect of decreased diffusivities was 
a relatively small.  Both 1 and 2 magnitude decreases led to only about -3.5% change in the 
effective radius.  The similarity of -2, -1, and 0 magnitude differences confirms a lack of 
effectiveness of our nanoparticle delivery method.  In the -1 and -2 magnitude diffusivity case, 
the nanoparticles barely diffuse out of the scaffold before releasing BCNU so if the effective 
radius of these cases are only a little bit different, then our nanoparticle method may not be very 
effective. 
 
III.D.ii Release Delay 
 The time when drug began to be released from the nanoparticles was adjusted by 12 hour 
increments, and as can be seen in Figure 14B effective distance increases with the time of 
delay.  Compared to the 0 hour case, where drug diffusion is almost completely unprotected from 
degradation in the tissues, our 36 hour delay model only had a 3.6% higher effective radius.  This 
fact supports previous findings that a nanoparticle formulation is not helpful.  The positive slope 
of the plot and 48 hour delay’s 3% increase on effective radius point towards increasing the 
delay in drug release as an effective way to improve the delivery mechanism. 
 
III.D.iii Degradation Rate 
 The data in Figure 14C shows degradation rate to have had a near linear effect on the 
effective radius.  Though not a 1:1 ratio, it is apparent that, for example, if our rate coefficient is 
20% too high, then the actual radius of effectiveness for a nanoparticle delivery method could be 
15% greater. 
 
III.D.iv BCNU Concentration 
 When effective of drug concentration was modified, the resulting effective radii were 
seen to increase with increasing initial BCNU concentration (see the No [Nanoparticle 
Correction results in Figure 14D).  This was to be expected, however the ratio of concentration 
increase to effective radius increase is again less than 1:1.  Also, due to concerns about the side-
effects of high BCNU doses, actually increasing the administration of drug is likely a bad idea, 
so we tested the sensitivity of the effective radius to [BCNU]nanoparticle increases that coincided 
with proportionally decreased nanoparticle concentrations (Figure 14D).  In such alterations, the 
effect of altering the initial drug concentration relatively disappears. 
 
III.D.v Span of Quick Release from Nanoparticles 
When the amount of time that nanoparticles released their contents quickly (1.72%/hr) 
was adjusted and lengthened by various percentages in order to increase the percent of BCNU 
introduced to the tissue quickly, the effective range of the nanoparticle formulation was seen to 
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increase in a near linear fashion.  This was to be expected as increasing the amount of drug 
introduced quickly from 21.5% in the original case to 86% in the 300% time increase case would 
put more drug into the tissue.  However, even in the 300% increase case where 86% of the 
BCNU incorporated into each nanoparticle came out quickly after the 36hour delay, the effective 
range in the healthy tissue region only increased by about 10%.  Thus the lack of penetration of 
our nanoparticle model cannot be solely due to lack of complete release.  Perhaps particles with 
an even faster rate of BCNU release would be required for a nanoparticle formulation to be 
helpful.  
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IV. Conclusions and Design Recommendations 
IV.A Conclusions 
 
After completing our model without nanoparticles in a way that should be comparable to 
a normal Gliadel
®
 delivery, it was found that our numbers did not compare favorably.  The 
BCNU concentrations remained higher for the nanoparticle encapsulated case than the non-
encapsulated case.  There was an order of magnitude difference in BCNU concentration between 
the two by the two day mark.  On the other hand, and more importantly, the nanoparticle model 
only had an effective penetration radius of 0.00467m while the model without nanoparticle 
encapsulation had an effective penetration radius of 0.00727m.  Thus, the non-encapsulated 
method would kill more metastasizing glioma cells and better prevent tumor recurrence. 
It is possible that the lack of effectiveness for our nanoparticle system was an imbalance 
between the release rate from the nanoparticles and the degradation rate of the BCNU.  The 
release rate from nanoparticles might not have been high enough to compete with the 
degradation rate to bring BCNU concentration levels up to threshold. 
IV.B Design Recommendations 
 
Considering the reasons as to why the addition of the nanoparticle does not demonstrate 
any improvements over simple diffusion, one design recommendation for this drug delivery 
model is to change the n. It is possible that selecting a material that allows for a faster release of 
the BCNU will allow more of the drug to be in the tissue at a given time, so that it is not 
overpowered by the rate of drug degradation. 
An alternative design recommendation that we suggest is to change the composition of 
the nanoparticle. The results of our sensitivity analysis showed that the effective radius was 
particularly sensitive to nanoparticle diffusivity and initial concentration of BCNU loaded into 
the nanoparticles. However, the only way to increase nanoparticle diffusivity is to reduce particle 
size. But at 54nm in diameter, the nanoparticles that we are using are already very small, near 
realistic manufacturing limits, and increasing the initial concentration of drug risks damaging 
healthy brain tissue. So we recommend changing the structure of the nanoparticle, possibly with 
the inclusion of probes that target molecular signatures specific to tumor cells, to have selective 
uptake of the nanoparticle by the tumor cells, where the nanoparticles will then unload the 
drug
[14]
.  This method of drug delivery would allow the nanoparticles to move further out into the 
tissue, since they would not degrade until taken up by tumor cells, and would allow us to still use 
a smaller initial concentration of BCNU, since the drug would be released directly within the 
tumor cells. 
Our sensitivity analysis also showed that the effective radius is sensitive to the drug 
degradation rate. So another additional design recommendation is that instead of using BCNU, 
we use a drug like Paclitaxel. Not only does Paclitaxel have a much slower degradation rate, but 
it also is larger than BCNU, so it is much less subject to loss via transcapillary exchange
[15]
.  
These advantages would possibly allow for deeper penetration into the brain tissue, as well as an 
effective concentration that could be sustained for a longer period of time. 
For continued work with this nanoparticle drug-delivery model, we also recommend 
changing the diffusion-only assumption. Originally, we did not include convection in this model, 
thinking that convection in the brain would be minimal. However, upon further research, we 
learned that there is a convective condition in the brain following surgery. Transient edema, or 
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the accumulation of fluid, is associated with surgical trauma and, furthermore, there is an 
interstitial fluid flow that results from pressure gradients that are established in the presence of a 
tumor
[16]
.  So including convection in subsequent models could increase the effective distance of 
the BCNU in our model without nanoparticles, closer to that which is observed in the literature. 
IV.C Realistic Constraints 
 
If future work with this model of nanoparticle-encapsulated BCNU drug delivery shows 
that the nanoparticle contributes to increasing the effective distance of the drug, then there are 
still potential constraints in design. We have not yet investigated the effects of the minimally 
effective BCNU concentration on healthy brain cells. The established minimum concentration is 
the minimum needed to kill tumor cells, but it is also possible that healthy brain cells will also be 
destroyed. In this case, we will need to optimize the model so that we maximize the amount of 
tumor tissue destroyed, and minimize the amount of healthy tissue that is damaged.  
But assuming that health safety is not compromised, another potential constraint is the 
Food and Drug Administration approval process. Before pharmaceutical drugs and devices are 
allowed to be introduced for sale to the public, the FDA must approve or give them clearance. 
FDA standards mandate that this product must undergo stringent testing through at least three 
phases of trials before getting clearance or approval. These trials are typically costly and time-
consuming, on average costing around $154 million dollars, and taking 8 years from the time 
clinical trials begin until approval is received. 
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Appendix A. Mathematical Statement of Problem 
 
General Governing Equation (cylindrical coordinates): 
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For all constants, see Table 1 
 
Assumptions: 
 1. No bulk flow 
 2. Symmetric about z-axis (no change in θ direction) 
  
I. Nanoparticle through the scaffold, tumor, and normal brain tissue 
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 Where: 
                                                                                         
All were approximated with the Stokes-Einstein Equation,   
   
            
 
Boundary conditions: 
1.     
              
  
   
2.     
              
  
   
3.                                        
     
  
 
 
II. BCNU through the scaffold, tumor and normal brain tissue 
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( 
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 Where:  
   [          ]  [           ]           
o                                                    
o                
o               at any time and position will be obtained from pt I. 
o                 as a function of time out of the nanoparticles 
obtained from release profile from literature that was a ratio of mass 
remaining to initial mass.  Therefore it is multiplied by the initial mass 
of BCNU in the nanoparticle to get the total flux out per nanoparticle. 
o Assume    term drops out in the scaffold (No enzymatic breakdown). 
                                                                                        
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Boundary conditions: 
1. √           
      
  
   
2.     
      
  
   
3.     
      
  
   
4.             (All BCNU is initially encapsulated in nanoparticles) 
 
Table 1. Parameter values used in nanoparticle-encapsulated BCNU simulation.   
Parameter   Baseline value Reference 
    
DBCNU, scaffold Diffusivity 2.0x10
-10
 m
2
s
-1
 3 
DBCNU, tumor Diffusivity 6.75x10
-9
 m
2
s
-1
 3 
DBCNU, brain Diffusivity 2.5x10
-10
 m
2
s
-1
 3 
kBCNU Reaction rate 1.31 x 10
-4
 s
-1
 3 
Dnanoparticle, scaffold  Diffusivity 8.41x10
-12
 m
2
s
-1
 Stokes-Einstein 
Dnanoparticle, tumor Diffusivity 8.41x10
-12
 m
2
s
-1
 Stokes-Einstein 
Dnanoparticle, brain Diffusivity 8.41x10
-12
 m
2
s
-1
 Stokes-Einstein 
cnanoparticle, scaffold, initial Concentration 1.558x10
-3
 mol m
-3
 Designed parameter 
cBCNU, nanoparticle Concentration 2.5x10
8
 mg m
-3
 Designed parameter 
μwater Viscosity 10
−3
 Pa·s Known 
Fnano, PLA BCNU flux from PLA nanoparticle fpercent mass ·Minitial ·cn·NA Calculation 
cn Nanoparticle concentration COMSOL Output Calculation 
NA Avagadro's number 6.022x10
23 
mol
-1
 Known 
SA Nanoparticle surface area  Designed parameter 
Minitial Mass of BCNU in a single nanoparticle 2.06134x10
-14
 mg Designed parameter 
Ra Drug metabolism -kBCNU*cBCNU 3 
Fpercent mass flux out of nanoparticle expressed as 
percent of total mass out per second 
Varies with Time 10 
CBCNU, scaffold Concentration 1.92296x10
7 
mg m
-3 
 
 
Figure 15A shows the percent of BCNU released from the 54nm PLA nanoparticles over 
time as measured by Yan et al
[9]
.  As can be seen, there is an initial period of quick release 
followed by slow release.  The fpercent mass, flux out of the nanoparticle as needed for our 
mathematical solution, must be expressed as a percent of total mass out per second.  Thus, the 
absolute percentages released were turned into percentages released per time by taking the slopes 
of regression lines for both release rates as seen in Figure 15B.  We converted the slopes of this 
model (1.72%/hr for the quick release and 0.0499%/hr for slow release) to percentages per 
second (0.000477778%/sec for the quick release and 1.38611%/sec for the slow release).  We 
incorporated in a 36 hour period with zero release to add in a theoretical shell that could 
postpone drug release, and the resulting flux function became that shown in Figure 15C. 
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Figure 15. Flux out of 54nm PLA Nanoparticles from Yan et al
[9]
.  A) Accumulated Drug Release Percentage 
over Time of two different nanoparticle formulations.  The circles represent the 54nm particles used in our model.  
B) Percent BCNU Released from Nanoparticle over Time with regressions lines used for establishment of flux 
per time function.  C) Plot of the Flux Function inputted into COMSOL A stepwise function was generated from 
the graph shown in B) 
  
A) 
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Appendix B. Solution Strategy 
 
To examine the release of BCNU from the pCPP:SA scaffold with and without the use of 
nanoparticles,  COMSOL Multiphysics 3.5A was used to solve a 2D-axisymmetric transient 
diffusion problem with reaction.  
Linear System Solver: The direct (UMFPACK) solver was used to solve the equations and did 
so with coupling of nanoparticle concentration with BCNU calculations at each time step. 
Time Stepping: The nanoparticle model was run over a period of 10 days, with solutions saved 
at every hour. The initial and maximum time step, set to AUTO, were determined by COMSOL.  
Relative Tolerance: 0.01 
Absolute Tolerance: 0.0010 
Mesh: We used free meshes with higher numbers of elements in the scaffold and tumor regions 
where concentration gradient would be the largest.  To accomplish this, triangular advancing 
front meshing was used and a maximum element size in the scaffold region was set along with a 
maximum growth rate in the tumor and healthy tissue regions.  The maximum element size was 
set to 0.00004m and the growth rate in the tumor and healthy regions was set to 1.05 for the 
nanoparticle case.  The maximum element size was set to 0.000025m and the growth rate in the 
tumor and healthy regions was set to 1.02 for the no nanoparticle case. 
 
Figure 16. The Final Meshes. A) Final Mesh for Nanoparticle Model with 2220 elements. B) Final Mesh for No 
Nanoparticle Model with 6818 elements 
 
 
The above meshes were garnered after tracking average BCNU concentration in the 
tumor region and flux across the tumor/healthy tissue interface for a number of different 
maximum element sizes and comparing the relative percent changes in tracked values.  Data for 
mesh convergence analysis on average BCNU concentration in the tumor region can be seen in 
Table 2, Table 3, and Figure 12. 
 
Table 2. Mesh Convergence Data for Model with Nanoparticles. 
Max. Element Size Number of Elements Avg [BCNU] (mg/m^3) Relative % Change 
1.50E-03 198 4.67E+03 0 
1.50E-04 560 4.68E+03 0.097560976 
5.00E-05 1628 4.68E+03 0.097560976 
A) 
B) 
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4.00E-05 2220 4.67E+03 0 
2.00E-05 6386 4.68E+03 0.195121951 
2.00E-05 9394 4.68E+03 0.195121951 
1.50E-05 10712 4.66E+03 -0.195121951 
1.00E-05 21539 4.68E+03 0.195121951 
 
Table 3. Mesh Convergence Data for Model without Nanoparticles. 
Max. Element Size Number of Elements Avg [BCNU] (mg/m^3) Relative % Change 
1.00E-05 14640 1.63E-02 0.586273488 
1.50E-04 1050 1.62E-02 -0.561173523 
1.00E-04 1424 1.60E-02 -1.390902651 
2.50E-05 6818 1.62E-02 0 
2.00E-05 9394 1.61E-02 -0.838927774 
8.00E-06 40417 1.61E-02 -1.016085853 
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Appendix C. Additional Visuals 
Appendix C1: Design Parameter Formulation 
 
In order to keep in accordance with Gliadel
®
 where a maximum of 8 wafers can be 
implanted for a total mass of BCNU of 61.5mg, we needed to ensure that our input values would 
correspond to the same total mass.  Therefore, after choosing a concentration of BCNU within 
the nanoparticles, only a specific concentration of nanoparticle would lead to a total mass of 
61.5mg.  To find this concentration, we started with the total mass and concentration within the 
nanoparticles: 
  
CBCNU, total = 61.5 mg 
CBCNU, nanoparticle = 2.5 x 10
8
 
  
  
 
Then we determined the necessary volume of all nanoparticles for such a concentration to lead to 
a total mass of 61.5mg. 
                   (
   
             
)                 
This value, coupled with the volume of a single 54nm diameter nanoparticle was used to figure 
to figure out the total number of nanoparticles. 
      
 
 
     
 
 
                                    
 
           
     
                               
Dividing this by the volume of our scaffold would yield the nanoparticle concentration. 
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This concentration was then converted to moles/m
3
 so that the number inputted into COMSOL 
could be smaller and more manageable. 
                     
  
  (              
             
  
  
     
                            
  
   = 1.558         
                     
  
 
For our reaction term, Minitial, the mass initially contained in each nanoparticle, was obtained by 
multiplying the volume occupied by each nanoparticle by the concentration of BCNU within 
each. 
        
            
 = 2.06134 x 10
-14
 mg 
Finally, we also needed to get a concentration of BCNU for our no nanoparticle case.  This was 
accomplished by dividing the total BCNU concentration (61.5mg) by the volume of the scaffold. 
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Appendix C2: Analytical Solution of Model Without Nanoparticle 
Using the following equation that models simple diffusion, we determined the analytical 
solution of BCNU diffusion through the scaffold, tumor and healthy brain regions. The following 
equation is used for each of the three regions. 
  
   
  
 √
 
   
 
 
 
In the scaffold region, the parameters are as follows: 
 
 
 
This gives us a concentration ca at the scaffold/tumor boundary of ca1 = 8560255.653 mg/m
3
 
ca = BCNU concentration 
ca0 = initial BCNU concentration 
k = reaction rate of BCNU 
D = diffusivity of BCNU through region 
x = distance BCNU has diffused 
ca0 = 1.92296 x 10
7
 mg/m
3 
k = 1.31 x 10
-4
 1/s 
D = 2.0 x 10
-10
 m
2
/s 
x = 1.0 x 10
-3
 m (thickness of the scaffold region) 
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Then we use this concentration as the initial BCNU concentration for the tumor region, 
where the parameters are as follows: 
 
 
 
This gives us a concentration ca at the tumor/health brain boundary of ca2 = 6478630.291 mg/m
3
 
 
We then use this concentration as the initial BCNU concentration for the healthy brain 
region, where we wish to solve for the distance at which the concentration is the minimally 
effective concentration of BCNU. The parameters for the equation are as follows: 
 
 
 
 
 
This gives us an effective distance of 1.018 cm from the outer tumor edge. 
 
Appendix C3: Original Design 
 
Originally, our design involved a solid, hemispherical PLA scaffold containing pCPP:SA 
nanoparticles and or modeling was a 3-scale problem.  The first was diffusion of nanoparticle 
through the scaffold and brain tissue.  The second was diffusion of BCNU though the scaffold 
and brain tissues.  This level involved a generation term for BCNU that was similar to the one 
for our current model.  It contained a degradation term and a function to account for flux out of 
nanoparticles. However, unlike the current model, COMSOL was used to determine this function 
as opposed to data from previous studies such as Yan et al
[9]
.  To get the flux function, 
Nanoparticles were modeled in COMSOL with uniform initial concentration and a simplification 
of [BCNU] outside the nanoparticles being set to zero.  Then the flux at the outer surface over 
time was used for the generation term.  
 
 
 
Figure 17. A&B) Old PLA Scaffold Schematic and Simplified Schematics for Macroscale Level of Diffusion 
through Scaffold and Brain Tissues. The scaffold was a solid hemisphere made out of PLA and the nanoparticles 
were 50µm in diameter and made of pCPP:SA.  All other dimensions were unchanged.  C) Schematic for BCNU 
c=0 
50.0 um 
ci=co 
A) B) C) 
ca1 = 8560255.653 mg/m
3 
k = 1.31 x 10
-4
 1/s 
D = 6.75 x 10
-10
 m
2
/s 
x = 2.0 x 10
-3
 m (thickness of the tumor region) 
ca2 = 8560255.653 mg/m
3 
ca = 5392.8 mg/m
3
 
k = 1.31 x 10
-4
 1/s 
D = 2.5 x 10
-10
 m
2
/s 
 
25 
 
diffusion within nanoparticle.  Diffusion of BCNU, originally at constant concentration, out of nanoparticles was 
modeled by setting the outer concentration to zero  
 
It was found that near complete diffusion of BCNU out of the nanoparticles took less 
than 2 minutes which did not give the nanoparticles time to diffuse out of the scaffold before 
drug release.  In light of this finding, we decided to change the nanoparticle material to PLA, 
which could be modified to have delayed release using shells of various materials.  We found a 
paper, Yan et al., describing release from 54nm PLA nanoparticles
[9]
, and we decided to use a 
shell model for our scaffold in order to place the nanoparticles closer to the brain initially.  Then 
we added a time delay to the flux from the nanoparticle in order to represent the delay conferred 
by a shell before arriving at the current study. 
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